Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
REGULATORY
Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment
Pfizer’s oral alopecia areata (AA) therapy Litfulo (ritlecitinib) is expected to face a price reduction based on its cost-effectiveness assessment (CEA) results, which showed a poor CEA profile for adults, who account for more than 90% of target patients. Litfulo…
To read the full story
Related Article
- Litfulo’s Price to Be Trimmed 3.8% in June after CEA
March 13, 2025
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
REGULATORY
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Takaichi Vows Cross-Party Talks on Social Security Reform
October 27, 2025
- Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
October 27, 2025
- Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
October 27, 2025
- Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
October 27, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…